source
- TRexBio raises $117 million in IPO as Retension secures $45 million Nasdaq debut for hypertension therapyTRexBio completed its initial public offering on Thursday, pricing the shares at a level that generated about $116.7 million in gross proceeds. The funding will support the company’s development of…
- Fierce Biotech outlines criteria for its 2026 Fierce 15 list, spotlighting top innovatorsThe Fierce Biotech editorial team released its 2026 Fierce 15 list and discussed the selection process on a recent episode of "The Top Line" podcast. More than 150 high‑quality entries were review…